Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA – Get Rating) – Equities research analysts at Oppenheimer decreased their FY2026 earnings estimates for Ayala Pharmaceuticals in a research note issued on Tuesday, May 17th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of $0.82 for the year, down from their previous estimate of $0.87. Oppenheimer currently has a “Outperform” rating and a $16.00 price objective on the stock.
Several other equities analysts have also weighed in on AYLA. Raymond James reduced their price objective on shares of Ayala Pharmaceuticals from $24.00 to $6.00 and set an “outperform” rating for the company in a research report on Wednesday, March 30th. Zacks Investment Research cut Ayala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 1st. Finally, Maxim Group reduced their price objective on Ayala Pharmaceuticals from $22.00 to $12.00 in a research note on Wednesday, March 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $16.63.
Ayala Pharmaceuticals (NASDAQ:AYLA – Get Rating) last released its earnings results on Monday, March 28th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.05). Ayala Pharmaceuticals had a negative net margin of 1,403.90% and a negative return on equity of 105.02%.
Several institutional investors have recently bought and sold shares of AYLA. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Ayala Pharmaceuticals by 406,248.7% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,153,648 shares of the company’s stock worth $18,328,000 after buying an additional 2,153,118 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Ayala Pharmaceuticals by 36.5% in the third quarter. Wellington Management Group LLP now owns 961,609 shares of the company’s stock worth $10,905,000 after purchasing an additional 257,246 shares in the last quarter. DLD Asset Management LP acquired a new position in Ayala Pharmaceuticals during the fourth quarter worth $1,347,000. Marshall Wace LLP acquired a new stake in shares of Ayala Pharmaceuticals in the fourth quarter worth about $420,000. Finally, CSS LLC IL bought a new stake in shares of Ayala Pharmaceuticals during the 4th quarter worth about $131,000. Institutional investors and hedge funds own 56.07% of the company’s stock.
Ayala Pharmaceuticals Company Profile (Get Rating)
Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (AYLA)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.